Skip to main content
Premium Trial:

Request an Annual Quote

DNA Manufacturer OriCiro Genomics Raises ¥800M in Series B Round

NEW YORK — OriCiro Genomics, a Japanese manufacturer of DNA for therapeutic and synthetic biology applications, said on Tuesday that it has raised ¥800 million ($7.3 million) in Series B funding and secured a ¥200 million long-term loan.

The financing round was led by University of Tokyo Edge Capital Partners and included ITOCHU Technology Ventures. The loan was provided by Japan Finance, a government-affiliated financial institution.

OriCiro was founded in late 2018 to develop and commercialize a proprietary technology for the cell-free assembly and amplification of large circular DNA. The so-called OriCiro Cell-Free Cloning System has applications in the pharmaceutical, diagnostic, agriculture, and food industries, according to the Tokyo-based company.

OriCiro said it will use the proceeds of the Series B round and loan to expand its manufacturing capabilities, advance its R&D, establish a US subsidiary, expand its intellectual property estate, and bring on new hires. It is also planning to launch a new plasmid DNA supply business aimed at the pharmaceutical and drug discovery markets.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.